Veracyte, Inc. — Cyborg Score 8/10

Strong
Molecular Diagnostics / Genomic Cancer Testing

Strategic Profile

The company raised its full-year 2025 revenue guidance to a range of $506 million to $510 million, driven by its core tests like Decipher and Afirma, all while maintaining a strong gross margin of 68.5%. Recent inclusion of their Decipher prostate test in NCCN guidelines and the strategic push into minimal residual disease (MRD) testing demonstrates their business model evolution.

Cyborg Score Rationale

2025 revenue reached $517.1 million (16% growth), with testing revenue of $493.2 million (18% growth) driven by Decipher Prostate and Afirma tests. Net income for Q4 2025 was $41.1 million (705% improvement) representing 29.3% of revenue. Profitability inflection achieved with strong margins and growth trajectory.

Top Insights

  • 2025 revenue of $517.1 million (+16% YoY) with net income of $66.4 million (+175% YoY) demonstrating strong profitability inflection
  • Revenue overwhelmingly driven by core testing business; Decipher and Afirma genomic classifiers represent nearly 97% of total revenue
  • Strategy includes expanding Decipher to metastatic prostate cancer population and launching new products expected to generate $20-40 million incremental revenue within two years
  • Free cash flow of approximately $91.57 million underscores ability to generate cash crucial for reinvestment into research and development

Named Competitors

  • Comprehensive Cancer Genomic Testing — Broad oncology genomic testing portfolio
  • Melanoma and Solid Tumor Diagnostics — Precision diagnostics for cancer prognosis
  • Cell-Free DNA Oncology Testing — Advanced blood-based cancer diagnostics

Recent Developments

  • (March 2026) Full-year 2025 results announced with $517.1 million revenue and strong profitability
  • (January 2026) Management presented at 44th Annual J.P. Morgan Healthcare Conference
  • (2025) Decipher Prostate test included in NCCN guidelines; multiple clinical presentations at ASCO and EAU conferences

Open the full interactive Veracyte, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →